07:00 , Aug 15, 2005 |  BC Week In Review  |  Clinical News

Iressa gefitinib: Post-marketing study data

Data from tumor samples of 39 NSCLC patients showed a correlation between low expression levels of the epithelial membrane protein 1 ( EMP1 ) and the probability of high response to treatment (p=0.04). None of...
07:00 , Aug 15, 2005 |  BC Week In Review  |  Clinical News

Iressa gefitinib: Post-marketing study data

Data from a study in 103 patients with various types of NSCLC resistant to Iressa showed that epithelial membrane protein 1 ( EMP1 ) was expressed in 66% of patients with squamous cell carcinomas and...
07:00 , Aug 15, 2005 |  BC Week In Review  |  Clinical News

AstraZeneca preclinical data

Researchers published in the Proceeding of the National Academy of Sciences the identification of epithelial membrane protein 1 ( EMP1 ) as a biomarker of resistance to Iressa gefitinib. In a mouse model of prostate...
07:00 , Aug 15, 2005 |  BioCentury  |  Product Development

Iressa insights

Ever since Iressa gefitinib received accelerated approval in 2003 for non-small cell lung cancer, AstraZeneca plc has been trying to find a way to identify the 10% of patients who respond to the drug, which...
00:43 , Aug 9, 2005 |  BC Extra  |  Clinical News

Researchers find marker for Iressa resistance

Researchers published in the Proceedings of the National Academy of Sciences the identification of epithelial membrane protein 1 ( EMP1 ) as a biomarker of resistance to Iressa gefitinib from AstraZeneca (LSE:AZN; AZN). In a...